439
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Bausch Health's recently active trials. Comparator arms are excluded.
- Brodalumab5 trials
- IDP-126 Gel4 trials
- IDP-126 Vehicle Gel4 trials
- Miebo3 trials
- NOV033 trials
- TENEO 317 Model 2 excimer laser2 trials
Upcoming readouts
Next primary completion dates among Bausch Health's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
Top therapeutic areas
Conditions studied most often across Bausch Health's recently active trials.
- Cataract9 trials
- Acne Vulgaris8 trials
- Psoriasis6 trials
- Astigmatism6 trials
- Myopia5 trials
- Dry Eye Disease4 trials
Bausch Health trials
The 50 most significant of Bausch Health's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial ParticipantsNCT07717918BL1332 eye drops | Phase 1 | Not yet scored | OngoingRecruiting | 28 est. | Aug 2026 |
| CHARMClindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne VulgarisNCT07205107clindamycin phosphate, adapalene and benzoyl peroxide | — | Not yet scored | OngoingActive, not recruiting | 200 est. | Aug 2026 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy VolunteersNCT06978244BL1332 ophthalmic solution | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 24 est. | Nov 2026 |
| Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive KeratectomyNCT06618547TENEO 317 Model 2 excimer laser | Na | Locked · track to reveal | OngoingNot yet recruiting | 140 est. | Nov 2026 |
| Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without AstigmatismNCT05264623TENEO 317 Model 2 excimer laser | Na | Locked · track to reveal | OngoingActive, not recruiting | 140 est. | 20 Nov 2026 |
| Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative ColitisNCT04314375Low Dose Budesonide | Phase 4 | Locked · track to reveal | OngoingRecruiting | 70 est. | Dec 2026 |
| A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in ChildrenNCT06305663Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic) | Na | Locked · track to reveal | OngoingRecruiting | 418 est. | 31 Jan 2027 |
| A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive KeratectomyNCT07412496Topical Ocular BL1332 low dose | Phase 2 | Locked · track to reveal | OngoingNot yet recruiting | 123 est. | Feb 2027 |
| NGL-Long TermA Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye DiseaseNCT07111013Lifitegrast/perfluorohexyloctane (PFHO) | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Apr 2027 |
| Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute DiarrheaNCT07285785Rifaximin 200 mg Tablet | Phase 4 | Locked · track to reveal | OngoingRecruiting | 54 est. | 20 Apr 2027 |
| A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic AstigmatismNCT07377474TENEO 317 Model 2 (1.28 US) Excimer Laser | Na | Locked · track to reveal | OngoingNot yet recruiting | 32 est. | Sept 2027 |
| IC-8 Apthera IOL New Enrollment Post Approval StudyNCT06060041 | — | Not yet scored | OngoingRecruiting | 435 est. | 30 Sept 2027 |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)NCT07428538Larsucosterol | Phase 3 | Locked · track to reveal | OngoingRecruiting | 350 est. | Nov 2027 |
| Study to Assess Safety, Pharmacokinetics, and Treatment Effect of CabtreoNCT07524946CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%. | Phase 4 | Locked · track to reveal | OngoingNot yet recruiting | 100 est. | Dec 2027 |
| PEER10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used PimecrolimusNCT00568997Pimecrolimus | — | Not yet scored | OngoingActive, not recruiting | 8,000 est. | Dec 2027 |
| An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric SubjectsNCT03240809Brodalumab | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 2 est. | Dec 2028 |
| Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative ColitisNCT05976802High dose budesonide rectal foam | Phase 4 | Locked · track to reveal | OngoingNot yet recruiting | 100 est. | Jun 2029 |
| Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive DisorderNCT02129751bupropion hydrobromide | Phase 4 | Locked · track to reveal | OngoingNot yet recruiting | 246 est. | Jul 2029 |
| LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisNCT03254667Brodalumab | — | Not yet scored | OngoingEnrolling by invitation | 3,500 est. | 10 Nov 2030 |
| Revive Toric RWE StudyNCT06785194REVIVE samfilcon B custom toric contact lenses | — | Not yet scored | OngoingNot yet recruiting | 30 est. | Jul 2026 |
| A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency TreatmentNCT07187297Thermage FLX | Na | Locked · track to reveal | OngoingRecruiting | 164 est. | Jun 2026 |
| Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract ExtractionNCT06333015enVista Beyond EY (EDF) IOL | Na | Locked · track to reveal | Completed | 304 est. | 11 Jun 2026 |
| A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseNCT07128628Lifitegrast/Perfluorohexyloctane Fixed Dose Combination | Phase 2 | Locked · track to reveal | Completed | 443 est. | 28 May 2026 |
| A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin ResurfacingNCT07214272Fraxel® FTX Laser System | Na | Locked · track to reveal | OngoingActive, not recruiting | 49 est. | 20 May 2026 |
| A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque PsoriasisNCT03987763IDP-122 Lotion | Phase 4 | Locked · track to reveal | OngoingRecruiting | 45 est. | May 2026 |
| Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07168902BL1107 Low dose | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 252 est. | May 2026 |
| A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque PsoriasisNCT03988439IDP-118 Lotion | Phase 4 | Locked · track to reveal | Completed | 16 est. | 6 Feb 2026 |
| RED-C-3132Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With CirrhosisNCT05297448Rifaximin SSD | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 466 est. | Jan 2026 |
| A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.NCT06565650Miebo | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 216 est. | Nov 2025 |
| A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens WearNCT07054606Perfluorohexyloctane ophthalmic solution | Phase 4 | Locked · track to reveal | Completed | 104 est. | 3 Nov 2025 |
| RED-C-3131Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisNCT05071716Rifaximin SSD | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 524 est. | Sept 2025 |
| A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular RednessNCT06803654BTOS-HA | Phase 3 | Locked · track to reveal | Completed | 578 est. | 29 Jun 2025 |
| A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract ExtractionNCT06594185enVista Aspire EA or Aspire Toric ETA IOLs | Na | Locked · track to reveal | Completed | 335 est. | 21 May 2025 |
| A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract ExtractionNCT06333028enVista Aspire EA IOLs | — | Not yet scored | Completed | 82 est. | 13 Mar 2025 |
| A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive AccuracyNCT06346340Miebo | Phase 4 | Locked · track to reveal | Completed | 97 est. | 24 Feb 2025 |
| CARECanadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work ProductivityNCT05132231Brodalumab | — | Not yet scored | OngoingActive, not recruiting | 394 est. | 5 Feb 2025 |
| Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) LensNCT06479148enVista® Aspire™ | Na | Locked · track to reveal | StoppedTerminated | 27 est. | 12 Dec 2024 |
| (IBS-C)Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)NCT03596905Plecanatide | Phase 2 | Locked · track to reveal | Completed | 218 est. | 25 Nov 2024 |
| Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative ColitisNCT04857112Low Dose MT-1303 | Phase 2 | Locked · track to reveal | Completed | 322 est. | 3 Sept 2024 |
| Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokeratology LensNCT05984290orthokeratology lens | Na | Locked · track to reveal | Completed | 90 est. | 27 Jun 2024 |
| A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye DiseaseNCT06309953Miebo | Phase 4 | Locked · track to reveal | Completed | 99 est. | 17 Jun 2024 |
| A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting SolutionNCT05565937BL-3100-NBR03 multi-purpose solution | Na | Locked · track to reveal | Completed | 295 est. | 28 Feb 2024 |
| Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment AlgorithmNCT04617080SUPRACOR Regular | Na | Locked · track to reveal | Completed | 60 est. | 28 Feb 2024 |
| Effects of NOV03 on the Tear FilmNCT05723770instillation of NOV03 | Phase 4 | Locked · track to reveal | Completed | 33 est. | 23 Dec 2023 |
| 1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact LensesNCT06053736REVIVE Contact Lens | Na | Locked · track to reveal | Completed | 26 est. | 15 Dec 2023 |
| Kalifilcon A Toric Compared to Commercially Available LensesNCT06098937Kalifilcon Toric Lens | Na | Locked · track to reveal | Completed | 30 est. | 27 Sept 2023 |
| Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic SolutionNCT05815758Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo) | Phase 3 | Locked · track to reveal | Completed | 512 est. | 18 Sept 2023 |
| Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell DiseaseNCT05098028Low Dose Rifaximin ER | Phase 2 | Locked · track to reveal | Completed | 44 est. | 4 Sept 2023 |
| Orientation Characteristics of Daily Disposable Toric Contact LensesNCT06069609kalifilcon A Daily Disposable Toric | Na | Locked · track to reveal | Completed | 30 est. | 15 Aug 2023 |
| A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular HypertensionNCT04140279Latanoprostene Bunod | Phase 4 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Aug 2023 |